Wellthy Therapeutics, a digital therapeutics company that uses a hybrid of artificial intelligence and human paramedical intervention to improve health literacy, appointed Vasudev V. Tribhuvan as Vice President, Partnerships & Alliances effective May 2018, said an official communiquÃ© of the company.
Commenting on the appointment, Abhishek Shah, Co-Founder and CEO of Wellthy Therapeutics, said, We have reached a point where digital pills greatly augment conventional drugs to target outcomes which were previously unheard of. Wellthy has already been pioneering outcomes beyond the pill in India. Vasudev’s rich experience in understanding of healthcare stakeholder problems, coupled with Wellthys world-class platform to solve for them has incredible potential to accelerate our impact goals, both in India and in Asia.
Previously Vasudev served at Biocon, where he was the Senior Director, Marketing and led strategic initiatives for the metabolic unit.
He is an alumni of the University of California, Los Angeles. Prior to Biocon, Vasudev held sales and marketing leadership roles with AstraZeneca, Boehringer Ingelheim and Novo Nordisk
For years, there has been a push within the pharmaceutical industry to move beyond the pill, to improve outcomes in chronic metabolic disorders. The impetus to move beyond the pill typically arises from the realizations that drugs alone do not suffice for patients to achieve optimal clinical outcomes. Pharma companies should consider integrating beyond-the-pill solutions as a differentiated package offering in chronic disease categories, also ensuring better outcomes, Vasudev V. Tribhuvan said.